Reversible Mitral and Aortic Regurgitation Due to Pioglitazone

ObjectiveTo report the occurrence of pioglitazone induced reversible valvular regurgitant lesions.MethodsClinical, laboratory, and imaging data are reported on a patient with known type 2 diabetes mellitus, who was prescribed pioglitazone to achieve better glyce mic control.ResultsWe present a case report of a 50-year-old woman, in whom diabetes had been diagnosed 5 years pre viously, who developed severe mitral and aortic regurgita tion during 5 months of treatment with pioglitazone along with clinical and laboratory indications of fluid retention. Echocardiography 5 months after discontinued use of pio glitazone showed regression of regurgitant lesions and nor malization of pertinent laboratory variables.ConclusionFive months of treatment with pio glitazone could potentially induce major cardiac valvu lar dysfunction, which was reversible in our patient. This report emphasizes the importance of carefully monitoring patients during treatment with thiazolidinediones. (Endocr Pract. 2012;18:e32-e36)